1-4 of 4
C. Karlsson
Close
Sort by
Journal Articles

ABT-737 Sensitizes B Cell Tumors for Killing by CD19-Retargeted T Cells,

Hannah S C Karlsson, Camilla Lindqvist, PhD, Gabriella Paul-Wetterberg, Helena Jernberg Wiklund, PhD, Kenneth Nilsson, MD, PhD, Bengt Simonsson, MD, PhD, Per Frisk, MD, PhD, Angelica Loskog, PhD
Journal: Blood
Blood (2011) 118 (21): 4032.
https://doi.org/10.1182/blood.V118.21.4032.4032
Published: 2011
Journal Articles

Aire-deficient mice develop hematopoetic irregularities and marginal zone B-cell lymphoma

Signe Hässler, Chris Ramsey, Mikael C. Karlsson, Disa Larsson, Björn Herrmann, Björn Rozell, Magnus Backheden, Leena Peltonen, Olle Kämpe, Ola Winqvist
Journal: Blood
Blood (2006) 108 (6): 1941–1948.
https://doi.org/10.1182/blood-2006-04-019679
Published: 2006
Includes: Supplemental data
Journal Articles

Treatment of Refractory Autoimmune Hemolytic Anemia in B-CLL with Alemtuzumab (Humanized CD52 MAb).

Jeanette Lundin, F. Celsing, C. Karlsson, A. Osterborg
Journal: Blood
Blood (2005) 106 (11): 2967.
https://doi.org/10.1182/blood.V106.11.2967.2967
Published: 2005
Journal Articles

Virus Reactivation Profile as Assessed by PCR and Serology Pattern Following First-Line Alemtuzumab (Anti-CD52 Monoclonal Antibody, Campath®) Therapy in Patients with B-CLL.

C. Karlsson, H. Dahl, A. Linde, J. Lundin, M. Björkholm, H. Mellstedt, A. Osterborg
Journal: Blood
Blood (2004) 104 (11): 968.
https://doi.org/10.1182/blood.V104.11.968.968
Published: 2004